Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2019

View Archived Issues

Knockout of presenilin-1 reduces T-cell acute lymphoblastic leukemia

EssexBio and Mitotech announce promising topline data from VISTA-1 phase III study

PIQUR announces treatment of first subject in first-in-human study of topical bimiralisib

Swedish MPA approves first-in-human trial of ILP-100

Mechanism of action exploration for the clinical-stage compound PRI-002

Discovery of novel P2X7R antagonists for the treatment of neurodegenerative disease

Biallelic variants in COX4I1 linked to a novel phenotype resembling Leigh syndrome

Guangzhou Maxinovel Pharmaceuticals patents PD-1/PD-L1 interaction inhibitors

New E3 ubiquitin-protein ligase Mdm2 inhibitors disclosed by Gan & Lee Pharmaceuticals

Asahi Kasei Pharma discovers prostanoid EP4 receptor agonists

Rpxds identifies dual FTO/COMT inhibitors

Inactivation of RBPJ leads to improper communication in brain pericytes and vascular malformations

GlaxoSmithKline patents receptor-interacting serine/threonine-protein kinase 1 inhibitors

CCR9 and OSM found to predict efficacy of PF-00547659 in patients with ulcerative colitis

At HIV Science meeting, lively discussion on what a cure will take

Biohaven receives complete response letter for Nurtec

China NMPA clears initiation of phase I bridging registrational study of Tibsovo

VISIBLE 2 trial of subcutaneous vedolizumab in Crohn's disease meets primary endpoint

Hypertrophic cardiomyopathy model shows potential of phosphomimetic-RLC gene therapy

Ascentage initiates phase Ib study in China with APG-1252 and osimertinib in NSCLC

U.S. approval for Otezla to treat oral ulcers associated with Behcet's disease

Hamlet reports outcome of phase I/II study of Alpha1H in bladder cancer

Tiziana reports preliminary topline data from phase IIa trial of milciclib in advanced HCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Aug. 19, 2025.
Subtyping beats a path toward precision medicine in Alzheimer’s
BioWorld MedTech
Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding subtypes in Alzheimer’s disease is all...
Marvel Biotechnology’s MB-204 as therapeutic agent for Alzheimer’s disease
BioWorld Science
Phosphorylation of the protein Tau is a key post-translational feature in tauopathies like Alzheimer’s disease (AD), which leads to microtubule dysfunction and...
CSL to shave off 3,000 jobs, Seqirus vaccine unit
BioWorld
CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than...